Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_2
2
67%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

completed267%
active_not_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
active_not_recruitingphase_2

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

NCT05087056
completedphase_3

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

NCT04707391
completedphase_2

Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

NCT03587207

Clinical Trials (3)

Showing 3 of 3 trials
NCT05087056Phase 2

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

Active Not Recruiting
NCT04707391Phase 3

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Completed
NCT03587207Phase 2

Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

Completed

All 3 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
3